SAMUEL V. CALABRESE, B.S.Pharm., M.B.A., FASHP (email@example.com) is the executive chief pharmacy officer for the Cleveland Clinic Enterprise in Cleveland, Ohio and holds an academic appointment at Northeast Ohio Medical University. He obtained his pharmacy degree from The Philadelphia College of Pharmacy and Science, his M.B.A. from Cleveland State University, and also obtained a certification in executive coaching from The Gestalt Institute of Cleveland. In his current role, he leads a pharmacy enterprise that encompasses a 1.5 billion dollar drug budget and 1,700 FTEs in 19 hospitals and clinics in Ohio, Florida, Nevada, Canada, England, and Abu Dhabi. Samuel is passionate about leadership development and has given several invited presentations and serves as the residency program director for Cleveland Clinic’s health-system pharmacy administration and leadership residency.
Calabrese’s ASHP service includes serving on the Commission on Affiliate Relations, the Council on Pharmacy Management, and as an ASHP delegate for Ohio. He has been an active member of the Section of Pharmacy Practice Leaders (SPPL) where he chaired the Section Advisory Group for Quality and Compliance and completed terms as director-at-large and chair for the SPPL. Calabrese is an active faculty with ASHP’s Pharmacy Leadership Academy and with ASHP’s Australia leadership boot camp. He is past president for both the Cleveland Society of Health-System Pharmacists (CSHP) and the Ohio Society of Health-System Pharmacists (OSHP). He received CSHP’s Evlyn Gray Scott Award in 2018 and OSHPs Walter M. Frazier Award in 2020.
Meet Samuel V. Calabrese
As we navigate through the healthcare landscape that has emerged due to the effects of COVID, we need to demonstrate that our profession is positioned to produce value to our organizations, to society, and to the bottom line. We need to capitalize on our skills and the confidence patients have in pharmacists to produce quality outcomes by adapting to virtual care settings and the new norms adopted during the pandemic. We have an obligation to our patients to provide the best care possible and deliver this in a way that meets their needs. This includes expanding our presence in outpatient clinics to collaboratively manage chronic disease, expanding care through telehealth, and evolving our practice model to focus on transitions of care. We must utilize resources wisely by leveraging technology and advancing technician roles to increase pharmacists’ direct patient care capacity. ASHP needs to continue to listen to the needs of the members to create meaningful educational materials, advocate for the profession, and be bold in establishing goals. Our attention must also focus on the impact we have financially on our patients and our health systems. We need to continue to fight for key issues such as provider status, reducing drug prices, and PBM reform. Finally, we need to have open meaningful conversations on diversity, equity, and inclusion in both our workplaces and professional organizations.
I am honored to be nominated for the ASHP Board of Directors and look forward to representing you on these key issues.